Expression of CLDN1 and Its Nuclear Distribution in Esophageal Squamous Carcinoma

ZHANG Da-wei, WU Jian, REN De-lian.et al

Abstract

To determine the expression of tight junction protein CLDN1 in esophageal squamous carcinoma (ESCC) and to explore the effect of CLDN1 on the biological function of ESCC TE-11 cells. MethodsThis study collected 30 ESCC tissues, 30 adjacent normal tissues and 30 distal esophageal tissues to detected the expression of CLDN1 in tissue microaary by immunohistochemistry method. Western blot was employed to determine the expression of CLDN1 in 15 ESCC tissues and cell lines, and then the distribution of CLDN1 in tumor cells and normal esophageal epithelial cells was analyzed. Lentivirus containing the sequence of CLDN1 shRNA was constructed and transfected into TE-11 cells, the transfection efficiency and intracellular distribution was determined by Western blot and flow cytometry. Cell proliferation was detected by CCK-8, the invasion and migration ability of cells was determined with Transwell. Cytoskeleton changes was observed by laser scanning confocal microscope. ResultsImmunohistochemical results showed no significant difference between the cancer tissues and adjacent tissues in term of the positive rate of CLDN1 ( P>0.05). CLDN1 was highly expressed in highly and moderately differentiated ESCC tissues, but its expression was significantly decreased in poorly differentiated cancer tissues. Western blot revealed that CLDN1 was mainly distributed in the nucleus of TE-11 cells. The proliferation of TE-11 cells, as well as invasion and migration ability, were declined obviously when the expression of CLDN1 being down-regulated, while the cytoskeleton protein fluorescence intensity deceased.ConclusionThe expression of CLDN1 in ESCC tissue is associated with its differentiation and may promote carcinogenesis in TE-11 cells.

 

Keywords: CLDN1, Esophageal squamous carcinoma, Tumorigenesis 


Full Text:

PDF


References


SAW ADA N. Tight junction-related human diseases. Pathol Int,2013,63(1):1-12.

SINGH AB, SHARMA A, DHAWAN P. Claudin family of proteins and cancer; an overview. J Oncol, 2010, 2010; 541957 [ 2016-01-11 ]. https://www. ncbi. nlm. nih. gov/pmc/articles/PMC2910494/. doi; 10. 1155/2010/541957.

К WON M. Emerging roles of claudins in human cancer. Int J Mol Sci»2013114(9): 18148-18180.

OUBAN A, AHMED A A. Claudins in human cancer: a review. Histol Histopathol,2010,25( 1) ;83-90.

AKASAKA H, SATO F. MOROHASHI S, et al. Anti- apoptotic effect of CLDN1 in tamoxifen-treated human breast cancer MCF-7 cells. BMC Cancer, 2010, 10; 548 [2016-03- 12]. https://www. ncbi. nlm. nih. gov/pmc/articles/ PMC 2 958956/. doi; 10.1186/1471-2407-10-548.

SUH Y.YOON C, KIM R, et al. CLDN1 induces epithelial- mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene, 2013,32 (41):4873-4882.

DHAWAN P. SINGH AB, DEANE NG, et al. CLDN1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest,2005,115(7); 1765-1776.

CHANG T, ITO К, КО T, et al. CLDN1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology,2010,138(1);255-65. el-e3 [ 2016-05-22 ]. http;//www. gastrojournal. org/article/ S0016- 5085(09) 01459-0/pdf. doi: 10. 1053/j. gastro. 2009. 08. 044.

CHAO YC, PAN SH, YANG SC, et al. CLDN1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med,2009,179 (2):123-133.

FORTEIR AM, ASSEI-IN E, CADRIN M. Keratin 8 and 18 loss in epithelial cancer cells increases collective cell migration and cisplatin sensitivity through claudinl up-regulation. J Biol Chem,2013,288(16): 11555-11571.

TSUKITA S, YAMAZAKI Y, KATSUNO T, et al. Tight junction-based epithelial microenvironment and cell proliferation. Oncogene,2008,27(55) : 6930-6938.

FORSTER C. Tight junctions and the modulation of barrier function in disease. Histochem Cell Biol, 2008, 130( 1 ); 55- 70.

YOC)N C, KIM M, PARK M, et al. CLDN1 acts through c- Abl-protein kinase Cdelta (PKCdelta) signaling and has a causal role in the acquisition of invasive capacity in human liver cells. J Biol (Them,2010,285( 1) :226-233.

KINUGASU T, AKAGI Y, OGHI T, et al. Increased CLDN1 protein expression in hepatic metastatic lesions of colorectal cancer. Anticancer Res,2012,32(6):2309-2314.

SHIOUS, SINGH A, MOORTHY K, et al. Smadl regulates CLDN1 expression in a transforming growth factor- beta-independent manner in colon cancer cells. Cancer Res, 2007,67(4);1571-1579.

BLANCHARD A, MA X, DUEXK K, et al. Claudin 1 expression in basal-like breast cancer is related to patient age. BMC Cancer, 2013, 13; 268 [ 2016-03-21 ]. https;//www. ncbi. nlm. nib. gov/pmc/articles/PMC3674926/. doi; 10. 1186/1471-2407-13-268.

ZHAO X, ZOU Y, GU Q, et al. Lentiviral vector mediated CLDN1 silencing inhibits epithelial to mesenchymal transition in breast cancer cells. Viruses,2015,7(6);2965-2979.

MYAL Y, LEYGUE E, BLANCHARD A. Claudin 1 in breast tumorigenesis; revelation of a possible novel "claudin high” subset of breast cancers. J Biomed Biotechnol, 2010, 2010; 956897 [ 2016-03-21 ]. https;//www. ncbi. nlm. nib. gov/pmc/articles/PMC2871677/. doi: 10. 1155/2010/956897.

GYORFFY H, HOLCZBAUER A, NAGY P, et al. Claudin expression in Barrett, s esophagus and adenocarcinoma. Virchows Arch,2005,447(6);961-968.

IKARI A, WATANABE R. SATO T, et al. Nuclear distribution of claudin-2 increases cell proliferation in human lung adenocarcinoma cells. Biochim Biophys Acta,2014 ,1843 (9):2079-2088.


Refbacks

  • There are currently no refbacks.